Avalo Therapeutics

Avalo Therapeutics

Avalo Therapeutics launched in 2011 as Cerecor Inc., a biopharmaceutical company founded by Dr. Blake Paterson. The firm initially developed treatments for pediatric neurological disorders, supported by a $32 million Series B round from investors including New Enterprise Associates and Apple Tree Partners (per Fierce Biotech, 2014). After an initial public offering in 2015, the company expanded into immunology through acquisitions, including the purchase of Aevi Genomic Medicine in 2018. Garry A. Neil, who joined as CEO in 2016 following leadership roles at AstraZeneca and Johnson & Johnson, oversaw the 2020 rebrand to Avalo Therapeutics, signaling a shift toward a precision medicine focus. The firm's strategy centers on developing therapies that modulate innate immune response, with its principal asset targeting the interleukin-33 (IL-33) pathway. AVTX-002, an anti-IL-33 monoclonal antibody, was the subject of a $640 million licensing agreement with GlaxoSmithKline in March 2020, covering global development for chronic inflammatory conditions like Crohn's disease. GSK terminated the deal in December 2020, returning rights to Avalo after a portfolio review (per Reuters, 2020). Avalo subsequently advanced the drug into a Phase 2 trial for acute respiratory distress syndrome. The company also holds AVTX-009, an anti-IL-1β monoclonal antibody, and legacy neurology assets. Avalo's geographic operations are centered in the United States, with clinical trial sites spanning Eastern Europe and the Asia-Pacific region. The company reported 44 employees across its Wayne, Pennsylvania headquarters and a research facility in Rockville, Maryland. Avalo's market capitalization, a direct proxy for its deployment capacity, has fluctuated between $10 million and $200 million, reflecting the binary outcome profile of a concentrated pipeline. In April 2023, the company completed a 1-for-240 reverse stock split to regain Nasdaq compliance, an operational event that underscored its capital-structure pressures (per the firm, April 2023). The firm has no disclosed philanthropic vehicles or club structures, operating with the transparency requirements of a Nasdaq-listed entity. Avalo's structural differentiator is its survival through a failed blockbuster licensing deal. The return of AVTX-002 by GSK collapsed the stock yet left the company holding a fully owned Phase 2-ready candidate that it had already validated through a major pharmaceutical partner. This inversion—where an external setback delivered a de-risked, unencumbered asset—is a rare capital-formation path for a micro-cap biotech, effectively giving public shareholders direct, undiluted exposure to a mechanism that had undergone extensive due diligence by a top-tier industry counter-party.